Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06124807 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2 study of Obesity and Overweight and Obesity, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
179
Enrollment target
20
Study locations

NCT06124807 is a Phase 2 study of Obesity and Overweight and Obesity that has completed, run by Eli Lilly and Company. The registered enrollment target is 179 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06124807, a Phase 2 study of Obesity and Overweight and Obesity, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
179 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

Conditions Studied

Obesity Overweight and Obesity

Interventions

  • DRUG Placebo
  • DRUG LY3305677

Study Locations (20)

Florida

  • Northeast Research Institute (NERI) - Fleming Island
  • Suncoast Clinical Research, Inc. - New Port Richey
  • Charter Research - Winter Park - Orlando
  • Charter Research - Lady Lake - The Villages

Arizona

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa - Chandler
  • Headlands Research - Scottsdale - Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson - Tucson

California

  • Velocity Clinical Research, Huntington Park - Huntington Park
  • Peninsula Research Associates - Rolling Hills Estates
  • Diablo Clinical Research, Inc. - Walnut Creek

Illinois

  • Great Lakes Clinical Trials - Andersonville - Chicago
  • Great Lakes Clinical Trials - Ravenswood - Chicago

New York

  • Dent Neurologic Institute - Amherst
  • North Suffolk Neurology - Port Jefferson Station

Hawaii

  • Pacific Diabetes & Endocrine Center - Honolulu

Kansas

  • Cotton O'Neil Diabetes & Endocrinology - Topeka

Kentucky

  • L-MARC Research Center - Louisville

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2023-11-17
Est. Completion 2025-07-09
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06124807

The ClinicalTrials.gov registry entry for NCT06124807 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06124807 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06124807 about?

NCT06124807 is a clinical study titled "A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight". The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3305677 compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.

What is the current status of trial NCT06124807?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2023-11-17. Estimated completion is 2025-07-09.

What conditions does trial NCT06124807 study?

This clinical trial studies the following conditions: Obesity, Overweight and Obesity.

What interventions are being tested in trial NCT06124807?

The interventions under investigation include: Placebo (DRUG), LY3305677 (DRUG).

Who is sponsoring clinical trial NCT06124807?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06124807 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight and Obesity

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.